“A welcome addition to the literature”: Sabinsa publishes safety data for ForsLean

By Stephen DANIELLS

- Last updated on GMT

Dr Muhammed Majeed, Sabinsa Corporation and Sami Labs founder, in a field of Coleus forskohlii. Image: Sabinsa
Dr Muhammed Majeed, Sabinsa Corporation and Sami Labs founder, in a field of Coleus forskohlii. Image: Sabinsa

Related tags Pharmacology

A new paper brings together the cumulative safety data of ForsLean, Sabinsa’s patented Coleus forskohlii extract, providing formulators with extra confidence in safety of the ingredient.

ForsLean, which has been a staple ingredient for Sabinsa for years, is an extract of the botanical Coleus forskohlii​ and is standardized to 10% or 20% forskohlin content. The new safety paper, published in the International Journal of Pharmacy and Pharmaceutical Research​,​ concludes that there were no signs of toxicity in the repeated doses of 28 days (acute study) and 180 days (chronic study) with Coleus forskohlii​ (containing 10% forskohlin).

As such, the authors stated that repeated oral exposure to this extract up to 1000 mg per kg of body weight per day does not produce any toxic effects. Therefore the extract was considered to have ‘No Observed Adverse Effect Level’ (NOAEL) under the test conditions employed.

In addition, no mutagenic activity has been observed for the ingredient, wrote the authors, led by Sabinsa Corporation and Sami Labs founder Dr. Muhammed Majeed. In other word, no adverse effects on DNA of the organism were found.

Michael McGuffin, president of the American Herbal Products Association, welcomed the publication of the data. ​Coleus forskohlii root is a well-established ingredient with a long history of safety. Even for such well known herbs though, additions to the scientific literature are always welcome and this article serves to increase our understanding of the appropriate use of this important herb and its extracts,”​ he said.

“While Sabinsa continues to innovate new efficacious ingredients, we are also committed to delivering the safest ingredients possible,”​ added Shaheen Majeed, Sabinsa’s Marketing Director.

“Our award-winning ForsLean brand is set apart from other suppliers of ​Coleus forskohlii with our safety publications, patents, and human clinical studies. Substitutions just don’t have those advantages.”

Source: International Journal of Pharmacy and Pharmaceutical Research
December 2015, Vol. 5, Issue 1, Pages 219-238
“Investigation of Acute, Sub-Acute, Chronic Oral Toxicity and Mutagenicity of ​Coleus forskohlii Briq. Hydroethanolic Extract, Standardized for 10% Forskolin in Experimental Animals”
Authors: M. Majeed, et al.

Related news

Related products

show more

Support children’s eyes & brains with Lutemax Kids

Support children’s eyes & brains with Lutemax Kids

Content provided by OmniActive Health Technologies | 27-Mar-2024 | Product Brochure

While nutrition has a key role in supporting eye and brain health, many children are not getting enough macular carotenoid-rich foods which may help protect...

Formulate for women’s health – formulate empowerment

Formulate for women’s health – formulate empowerment

Content provided by Verdure Sciences | 26-Mar-2024 | Product Brochure

Women’s health trends are mirroring bigger conversations of empowerment and wellbeing. Within the women’s health category, upticks in areas of lean muscle...

MOROSIL:INGREDIENT OF THE YEAR

MOROSIL:INGREDIENT OF THE YEAR

Content provided by BIONAP BIOACTIVE NATURAL PRODUCTS | 07-Mar-2024 | Product Brochure

MOROSIL™ has won as Ingredient of the Year in the category Weight Management at 2023 Nutraingredient USA. MOROSIL ™ is a standardized extract derived from...

In Weight Management Go Beyond with Slendacor®

In Weight Management Go Beyond with Slendacor®

Content provided by PLT Health Solutions | 22-Feb-2024 | White Paper

Slendacor® is a synergistic, patented formulation of three standardized herbal extracts: turmeric (Curcuma longa), moringa (Moringa oleifera) and curry...

Related suppliers

Follow us

Products

View more

Webinars